ADAM8 interacts with integrins through the disintegrin (DIS) domain, thereby activating integrin signaling pathways such as focal adhesion kinase (FAK), extracellular regulated kinase (ERK1/2), and protein kinase B (AKT/PKB) signaling, further contributing to cancer progression via the induction of angiogenesis, metastasis and chemoresistance [24,37]. Here, ADAM8 is linked to cancer.